Startup Funding News
Explore funding rounds, the companies behind them and the investors taking part.
- Rounds
- 473 All time
- Disclosed funding
- $19.6B 400 disclosed amounts
- Median round
- $20M Of disclosed amounts
| Company | Amount | Round | Sector | Country | Investors | Announced |
|---|---|---|---|---|---|---|
| E EnginZymeCompany profile EnginZyme develops cell-free biomanufacturing technology that uses immobilized enzymes to make chemicals and ingredients through scalable industrial processes. EnginZyme develops cell-free biomanufacturing technology that uses immobilized enzymes to make chemicals and ingredients through scalable industrial processes. | SEK 75M | Equity roundUndisclosed | Biotech | Sweden | Investors | |
| TT Tempo TherapeuticsCompany profile A regenerative-medicine company developing injectable microporous scaffolds that help the body rebuild tissue at damaged sites. A regenerative-medicine company developing injectable microporous scaffolds that help the body rebuild tissue at damaged sites. | ≤$2.3M | NCI SBIR grantUndisclosed | Biotech | United States | Investors | |
| BR Basecamp ResearchCompany profile Basecamp Research builds biological AI models from genomic data to help design therapeutics, including protein-based medicines. Basecamp Research builds biological AI models from genomic data to help design therapeutics, including protein-based medicines. | $140M | Series CSeries C+ | Biotech | United Kingdom | Investors | |
| E EnvedaCompany profile Enveda uses AI to discover biologically active molecules from nature and develop them into small-molecule medicines for inflammatory and metabolic diseases. Enveda uses AI to discover biologically active molecules from nature and develop them into small-molecule medicines for inflammatory and metabolic diseases. | $311M | Series ESeries C+ | Biotech | United States | Investors | |
| AL Azulene LabsCompany profile Physics-informed AI predicts molecular properties and chemical behavior for drug and materials research. Physics-informed AI predicts molecular properties and chemical behavior for drug and materials research. | $3.4M | Pre-SeedPre-seed | Biotech | — | Investors | |
| PB Primrose BioCompany profile Primrose Bio supplies manufacturing technologies for biologic drugs, mRNA products and vaccines. Primrose Bio supplies manufacturing technologies for biologic drugs, mRNA products and vaccines. | Undisclosed | Growth financingGrowth | Biotech | United States | Investors | |
| C CellsBinCompany profile A biotechnology company developing rare-cell detection and single-cell analysis tools for cancer monitoring. A biotechnology company developing rare-cell detection and single-cell analysis tools for cancer monitoring. | Undisclosed | Series A | Biotech | United States | Investors | |
| MT Molecular Targeting Technologies, Inc.Company profile A clinical-stage biotechnology company developing targeted radiopharmaceuticals for cancer treatment and diagnosis. A clinical-stage biotechnology company developing targeted radiopharmaceuticals for cancer treatment and diagnosis. | $3.2M | National Cancer Institute R01 grantUndisclosed | Biotech | United States | Investors | |
| I ImpriMedCompany profile A precision-oncology service that tests live cancer cells against drugs and uses clinical data to predict which treatments may work best for each patient. A precision-oncology service that tests live cancer cells against drugs and uses clinical data to predict which treatments may work best for each patient. | $10M | Series A2 bridgeUndisclosed | Biotech, Healthtech | South Korea | Investors | |
| AB Axio BioPharmaCompany profile A data platform that connects pharmaceutical manufacturers and their production partners while each organization keeps control of its own systems and records. A data platform that connects pharmaceutical manufacturers and their production partners while each organization keeps control of its own systems and records. | $2.4M | Pre-seed | Biotech, Enterprise software | United States | Investors |
Active investors in this selection
All investors →Ranked by rounds participated in · All time
- 1RA Capital Management
Estuary Biotherapeutics, Circle Pharma, Inc., Solstice Oncology
22rounds3led - 2Janus Henderson Investors
Star Therapeutics, OMass Therapeutics, Soufflé Therapeutics
15rounds1led - 3Eli Lilly and Company
BigHat Biosciences, Circle Pharma, Inc., Moonwalk Biosciences
15rounds0led - 4ARCH Venture Partners
Soufflé Therapeutics, Encoded Therapeutics Inc., Moonwalk Biosciences
14rounds0led - 5OrbiMed
Star Therapeutics, Leal Therapeutics, Accro Bioscience
11rounds1led
Latest digests
Archive →Explore published rounds while the next edition is being prepared.
Browse rounds by topic
Geography
Featured selections
Nordic Foodtech Fund II pairs early capital with scientific expertise
An EIF pledge of up to €30m supports a fund targeting €80m for science-led agrifood companies.
Read the research →